Compare Kroger Co (KR) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Novavax Inc — how do they compare? Kroger Co trades at $56.2 (market cap $34.60B), while Novavax Inc trades at $7.94 (market cap $1.30B). The key difference: Kroger Co is far larger — about 26.6× Novavax Inc's market cap, and Kroger Co pays a 2.55% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| KR | NVAX | |
|---|---|---|
Market Cap | $34.60B | $1.30B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $11.19 |
52-Week Low | $55.53 | $6.22 |
Enterprise Value | $54.70B | $879.40M |
Dividend Yield | 2.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.73, down 1.03% with bearish technical signals from moving averages. The company maintains stable revenue around $147B with recent earnings showing mixed results - beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Kroger demonstrates strong cash flow generation with $5.8B from operations in 2025 and pays consistent dividends, while expanding digital services and AI shopping assistance.
Kroger presents a defensive investment opportunity with 2.7% dividend yield and analyst consensus target of $68.63 (21% upside). However, rising debt levels and competitive pressures in grocery retail pose risks. The stock offers value with P/S of 0.25x but trades at premium P/E of 33x, requiring earnings acceleration to justify valuation.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
